Objectives. Outline. Sepsis Incidence and Outcomes. Definitions
|
|
- Sherman Henry
- 6 years ago
- Views:
Transcription
1 Objectives Evaluate recent literature on the management of sepsis Apply new and potentially controversial recommendations from the Surviving Sepsis Guidelines to patient cases. Surviving Sepsis Campaign Guidelines: Update (Early Goal Directed Therapy and Fluids) Simon Lam, PharmD Cleveland Clinic Outline Definitions, epidemiology, and pathophysiology Goals of therapy Protocolized, quantitative resuscitation Transfusion Fluid therapy choice Definitions Sepsis Systemic inflammatory response secondary to infection Severe sepsis Sepsis with organ dysfunction Septic shock Acute circulatory failure leading to ineffective tissue perfusion Hypotension unresponsive to fluid resuscitation Levy MM. CCM 23;31:125 6 Sepsis Incidence and Outcomes Hospital admissions for severe sepsis common and rising Over 75, cases per year Increased 13% per year from 24 to 29 Annual US costs exceed $24 billion Eleventh most common cause of death in the US Mortality rate depends on severity of illness Range 15% (sepsis) to 7% (septic shock and multi organ failure) Angus DC. CCM 21;29:133 1 Gaieski DF. CCM 213;41: Martin GS. NEJM 23;348: American Society of Health-System Pharmacists 1
2 Septic Shock Pathophysiology Features of each shock type Decreased preload Increased venous capacitance Loss of intravascular contents Impaired cardiac output Decreased stroke volume from low preload Cytokine induced myocardial dysfunction Vasodilation Inappropriate activation of vasodilatory mechanisms Failure of vasoconstrictive pathways Maldistribution of blood flow to organs or in the microcirculation Case MN is a 65 year old female presented to the emergency department with hospital acquired pneumonia Labs and vitals Temp 1.9 F (38.3 C) HR 15 beats/min RR 31 breaths/min BP 8/55 (mean 63 mm Hg) Lactate 5.5 mmol/l Intubated and placed on mechanical ventilation Landry DW. NEJM 21;345: Dellinger RP. CCM 23;31: Would you recommend placement of a central line and initiation of resuscitation protocol to target CVP and ScvO2? Yes No SSC Recommendations: Initial Resuscitation Protocolized, quantitative resuscitation of patients with sepsis induced tissue hypoperfusion Goals during the first six hours of resuscitation Central venous pressure (CVP) 8 12 mm Hg Goal mm Hg in mechanically ventilated patients MAP 65 mm Hg Urine output (UOP).5 ml/kg/hr Central venous oxygen saturation (ScvO2) 7% or mixed venous oxygen saturation (SvO2) 65% Dellinger RP CCM 213;41: Surviving Sepsis Campaign (SSC) Guidelines Joint collaboration between the Society of Critical Care Medicine and the European Society of Intensive Care Medicine Goal is to reduce mortality from sepsis by 25% Evidence based consensus guidelines for the management of severe sepsis and septic shock Third iteration of guidelines published in 213 Sponsored or endorsed by 3 international organizations % Mortality Severe Sepsis Mortality Over Time No. of patients Dellinger RP CCM 213;41: Kaukonen KM. JAMA 214;311: American Society of Health-System Pharmacists 2
3 Sepsis Progress in the Past 1.5 Decades 2 22 Rivers EGTD Annane Steroids PROWESS Leuven 1 ARMA SAFE Kumar Early ABX Leuven 2 CATS SSC CORTICUS SOAP II VASST SSC 2 NICE SUGAR VISEP PROWESS SHOCK Myburgh Voluven Perner Tetraspan SSC 3 Feb PROCESS ALBIOS ARISE TRISS Early Goal Directed Therapy (EGDT) Sepsis criteria Study Interventions Standard (S) Goals set (CVP, MAP, UOP) EGDT Addition of ScvO 2 to goals Protocol driven method for achieving goals Systolic BP 9 mm Hg Lactate 4 mmol/l Arterial catheter Central venous catheter CVP 8 12 mm Hg MAP <65 mm Hg 65 mm Hg ScvO 2 7% <8 mm Hg <7% Despite fluids (2 3 ml/kg) Crystalloids Colloids Vasopressors PRBC for Hct 3% <7% Dobutamine 6 Hours Rivers E. NEJM 21;345: % 4% 2% % EGDT Outcomes n = 263 Standard EGDT p=.3 p=.9 p= % 46.5% 49.2% 44.3% 3.5% 33.3% Hospital Mortality 28 Day Mortality 6 Day Mortality Rivers E NEJM 21;345: Controversies with EGDT Unclear intervention leading to study s positive findings Use of a goal directed protocol Addition of ScvO 2 monitoring Lactate clearance non inferior to ScvO 2 as a goal Both? High control arm mortality Use of CVP as a resuscitation goal Fluid responsiveness better predicted by dynamic markers Jones AE. JAMA 21;33: Durairaj L, Schmidt GA. Chest 28;133: Huang DT. ICM 213;39: PROCESS STUDY Hypothesis Is protocol based care superior to usual care Is EGDT with central hemodynamic monitoring better than protocol based therapy PROCESS Inclusion Criteria Site 31 centers 4, ED visits / year Use lactate as screening for cryptic shock No formalized sepsis resuscitation protocol No routine use of oximetric central venous catheter Patient Similar to Rivers study 18 yo 2 SIRS criteria Hypotension SBP < 9 mmhg or requiring vasopressor after fluid challenge (1 L) Enroll within 12h of arrival and 2h within shock Yealy DM. NEJM 214;37: Yealy DM. NEJM 214;37: American Society of Health-System Pharmacists 3
4 PROCESS 3 Arms PROCESS Differences in Therapy Protocol based EGDT OximetricCVC CVP: 8 12 mmhg MAP > 65 mmhg ScvO2 >7% Early Detection and Fluid Administration Protocol based Standard 2 large bore IV Fluids Vasopressors Transfusion goal (7.5 g/dl) Usual Care All decisions based on resuscitation team Protocol Implemented by Dedicated Team IV Fluids 6 Hours (L) EGDT Protocol Usual EGDT (n=439) Protocol (n=446) Usual (n=456) Pressor* 55% 52% 44% Dobutamine* 8% 1% 1% PRBC* 14% 8% 8% *p<.5 Yealy DM. NEJM 214;37: Yealy DM. NEJM 214;37: PROCESS Outcomes PROCESS Secondary Outcomes 6% 4% 2% 21% EGDT Protocol Usual p=.66 p=.83 32% 31% 18% 19% 34% Reaching MAP goal* EGDT Protocol Usual ICU Admission* 91% 85% 86% AKI* 3% 6% 2.8% *p<.5 % Hospital Mortality 9 Day Mortality Yealy DM. NEJM 214;37: Yealy DM. NEJM 214;37: PROCESS VS. RIVERS Rivers PROCESS Design Single Center Multi Center No. of patients Year APACHE II ScvO 2 49% 71% PRBC / Dobutamine 64% / 14% 14% / 8% Lactate (mmol/l) 7 5 Mortality usual care 46.5% 19% PROCESS Conclusions Early recognition, fluid, and antibiotics remain crucial No mortality difference observed when comparing protocolized resuscitation to usual care Progress of care may have discounted importance of strict hemodynamic monitoring and resuscitation goals Yealy DM. NEJM 214;37: Rivers E NEJM 21;345: American Society of Health-System Pharmacists 4
5 ARISE PROCESS PROMISE ARISE Near identical protocol compared to PROCESS 2 arm study EGDT and usual care Initiation of ABX mandated prior to randomization N=16 Peake SL. NEJM 214;371: ARISE Treatment / Outcomes More therapies used in EGDT group 2L vs. 1.7L Vasopressor: 76% vs. 66% PRBC: 14% vs. 7% Dobutamine: 15% vs. 3% 2% 15% 1% 5% % 9d mortality 18.6% 18.8% EGDT Usual SSC Response Required monitoring via CVC does not confer survival benefit in all patients who have received timely antibiotics and fluid resuscitation Results of PROCESS and ARISE trials have not demonstrated any adverse outcomes Therefore, no harm exists in keeping current SSC guidelines intact Yealy DM. NEJM 214;37: Possible SSC Clarifications Early recognition and antimicrobials remain cornerstones of therapy Resuscitation should be systematically targeted to clinician specified criteria for preload and evidence of hypoperfusion Blood pressure goals should be individualized to optimize perfusion NQF SEPSIS Measure lactate level Obtain blood cultures prior to antibiotics Administer broad spectrum antibiotics Administer 3 ml/kg crystalloids for hypotension of lactate > 4 mmol/l Apply vasopressor (for hypotension that does not respond to initial fluid resuscitation to maintain MAP > 65) Patients with septic shock or initial lactate > 4 mmol/l measure CVP and ScvO2 Remeasure lactate 214 American Society of Health-System Pharmacists 5
6 Case, continued The medical team inserted a central venous catheter in the right internal jugular vein Pertinent data HR 115 beats/min in sinus rhythm MAP 59 mm Hg UOP.3 ml/kg/hr CVP 3 mm Hg A venous blood gas was sent from the catheter ScvO 2 59% Lactate 6.3 mmol/l Which of the following is the recommended initial fluid choice for a patient with severe sepsis or septic shock? Hydroxyethyl starch 5% albumin Lactate Ringer s solution Normal saline SSC Recommendations: Fluids Crystalloids as the initial fluid of choice for resuscitation Against the use of hydroxyethyl starches (HES) Albumin in fluid resuscitation when patients have required substantial amounts of crystalloids Initial fluid challenge of at least 3 ml/kg crystalloid Fluid challenge technique Levy MM. CCM 23;31: % 1% % HES in ICU patients and Severe Sepsis Diverse ICU population HES p=.26 18% 17% 9 Day Mortality 7% n=7 p=.4 6% Renal Replacement Therapy 6% 4% 2% % Severe Sepsis HES Control n=84 p=.3 51% 43% 9 Day Mortality p=.4 22% 16% Renal Replacement Therapy Myburgh JA N Engl J Med 212;367: Perner A N Engl J Med 212;367: Albumin versus Saline for Fluid Resuscitation 28 Day Mortality Albumin Saline RR (95% CI) Overall 726/3473 (2.9) 729/346 (21.1).99 ( ) Severe sepsis Yes 185/63 (3.7) 217/615 (35.3).87 ( ) No 518/2734 (18.9) 492/272 (18.1) 1.5 ( ) Favors albumin Favors saline Significantly lower mortality favoring albumin on multivariate analysis of severe sepsis subgroup The SAFE Study Investigators. N Engl J Med 24;35: The SAFE Study Investigators. Intensive Care Med 211;37:86 96 Sepsis Fluid Resuscitation Meta Analysis Design Prospective randomized trials of albumincontaining solutions Only included patients with sepsis Results Seventeen studies with 1977 participants Allocation to albumin associated with a reduction in mortality Odds ratio.82 (95% confidence interval.67 1., p =.47) Delaney AP. CCM 211;39: American Society of Health-System Pharmacists 6
7 ALBIOS: Study Design Patients with severe sepsis / septic shock (6 24hr) ALBIOS Outcomes (n=1818) Albumin Albumin: [3 ml at 2% in 3* hr] + Crytalloids Placement of arterial line and CVC Randomization Volume Replacement (Rivers Protocol) Crystalloid Crystalloids Caironi P. NEJM 214;37: Treatment / Vitals 7d net fluid: 347 ml vs. 122 ml (p=.4) Lower HR (p=.2) Higher MAP (p=.3) Time to hemodynamic stability: 3d vs. 4d (p=.7) Mortality 5% p=.29 4% p= % 41.1% 3% 31.8% 32.% 2% 1% % 28d 9d Caironi P. NEJM 214;37: ALBIOS Subgroup 9 Day Mortality Albumin Crystalloid RR (95% CI) Overall 41.1% 43.6%.94 ( ) Time <6h 4.6% 4.6% 1. ( ) 6 24h 413% 35.%.92 ( ) Septic shock Yes 37.% ( ) No 518/2734 (18.9) 492/272 (18.1).87 (.77.99) Evidence Grade: Albumin Method Level 1: All evidence that supports what I already believe Level 3: All evidence that refutes what I already believe Favors.5 albumin 1 Favors 2 crystalloids Caironi P. NEJM 214;37: Should Chloride be Avoided? RIFLE Class Chloride Liberal (n = 76) Chloride Restrictive (n = 773) Risk 71 (9.) 57 (7.4).16 Injury 48 (6.3) 23 (3.).2 Failure 57 (7.5) 42 (5.4).1 Injury and Failure 15 (13.8) 65 (8.4) <.1 Data presented as n (%). Classification per the serum creatinine criteria of Risk, Injury, Failure, Loss, and End Stage (RIFLE). p IV Crystalloids and Mortality Outcome Balanced fluid (n=3365) No Balanced fluid (n=3365) Hospital Mortality 19.6% 22.8%.1 ARF with dialysis 4.5% 4.7% NS Hospital LOS (d) NS p No difference in mortality: 15% vs 13%, p=.44 Yunos NM. JAMA 212;38: Raghunathan K. CCM 214;42: American Society of Health-System Pharmacists 7
8 Hospital Mortality (%) IV Crystalloids and Mortality % 1% 2% 3% 4% 5% 6% 7% 8% 9% Percent of Total Fluid That is Balanced by Day 2 Raghunathan K. CCM 214;42: Possible SSC Clarifications Consider balanced fluids Patients with increased risk for renal dysfunction Large volume of saline have been given Electrolyte and acid/base abnormalities from saline administration Insufficient data to routinely recommend albumin supplementation post initial resuscitation Case, continued The patient was given a total of 4 liters of Ringer s Lactate over 3 hours Updated patient data MAP 65 mm Hg UOP.4 ml/kg/hr CVP 12 mm Hg Lactate 5.9 mmol/l ScvO 2 52% Hgb=7.7 g/dl Would you recommend giving PRBC to optimize oxygen delivery? Yes No SSC Recommendations: Transfusion During first 6 hours of resuscitation if central venous oxygenation is below goal despite volume repletion, transfusions to achieve HCT 3% is a treatment option Once tissue hypoperfusion has resolved, PRBC transfusion when Hgb < 7. g/dl is recommended Outcome TRISS Study Lower Hgb (n=52) Higher Hgb (n=496) #of PRBC <.1 Median PRBC / pt. 1 ( 3) 4 (2 7) p <.1 9d mortality 43% 45%.44 Ischemic events 7.2% 8.%.64 Vasopressor use Ventilator use RRT use NS NS NS Levy MM. CCM 23;31:125 6 Holst LB. NEJM 214;371: American Society of Health-System Pharmacists 8
9 SSC Recommendations: Transfusion For most critically ill patients a transfusion target when Hgb <7. g/dl seems reasonable Key Takeaways EGDT In the setting of early recognition and early fluids and antimicrobial administration, clinician driven resuscitation goals most likely sufficient Fluids Preliminary data suggest no additional harm and possible benefit with balanced crystalloids infusion Routine replacement of albumin not recommended PRBC Target of Hgb >7. g/dl most likely sufficient for most critically ill patients Surviving Sepsis Campaign Guidelines: Update (Early Goal Directed Therapy and Fluids) Simon Lam, PharmD Cleveland Clinic Adjunctive Therapies in the Management of Septic Shock Jeremy DeGrado, PharmD BCPS Clinical Pharmacy Specialist Critical Care Brigham and Women s Hospital Boston, MA Outline Antimicrobial therapy Hemodynamic support Vasoactive agents Corticosteroids Glycemic control The team wishes to initiate antimicrobial therapy for MN as soon as possible. Which regimen would you recommend? Ceftazidime + Vancomycin Cefepime + Levofloxacin + Vancomycin Ceftriaxone + Levofloxacin Gentamicin + Ceftazidime + Vancomycin 214 American Society of Health-System Pharmacists 9
10 Antimicrobials/Source Control Appropriate cultures prior to antimicrobials Does not delay initiation > 45 minutes Effective IV antimicrobials within first hour Patient specific factors Medication specific factors Double coverage when appropriate De escalation when appropriate Source control Dellinger RP, et al. Crit Care Med 213;41(2): Frequency Time from EGDT Qualification to Appropriate Antibiotics hr 1 2hrs 2 3hrs 3 4hrs 4 5hrs 5 6hrs Mortality 25% 37% 35% 42% 5% 67% Gaeiski DF, et al. Crit Care Med 21;38(3) Alive Dead Patient Case (continued) Initiated on norepinephrine at 5 mcg/min, titrated quickly up to 12 mcg/min MAP = 57 mm Hg CVP = 12 ScVO2 = 72% Urine output = 2 to 3 ml/hr Lactate = 5.3 ICU team is looking to initiate a second vasoactive agent due to low MAPs What is your recommendation for a second vasoactive agent and MAP goal? Phenylephrine for MAP > 65 mm Hg Epinephrine for MAP > 85 mm Hg Vasopressin for MAP > 65 mm Hg Dobutamine for MAP > 85 mm Hg Vasoactive Agents 28 SCCM Recommendations NE or DA as 1 st line agent EPI first alternative EPI, PE, VP not recommended as initial vasopressors VP as adjunctive therapy for effect equivalent to NE monotherapy Dellinger RP, et al. Crit Care Med 213;41(2): Dellinger RP, et al. Crit Care Med 28;36(1): SCCM Recommendations NE 1 st line agent EPI first alternative/substitution VP as adjunctive therapy to increase MAP & decrease NE VP not recommended as initial vasopressor DA and PE only in selected patient populations Goals of Cardiovascular Resuscitation Cumulative Survival (%) High target group Low target group No. at risk Day Low target High target Asfar P, et al. NEJM 214; 37: (adapted) 214 American Society of Health-System Pharmacists 1
11 Difference in 6 hour total equivalent volume (ml) Initiation of Vasopressors Overall p< Initiation Time of Vasoactive Agents (hrs after onset of hypotension Complications of Catecholamine Therapy Tachycardia/ tachyarrhythmias Reflex bradycardia (phenylephrine) myocardial oxygen supply myocardial oxygen consumption CO/CI Hollenberg SM, et al. Crit Care Med 24;32: Limb ischemia splanchnic blood flow lactate Dopamine Prolactin suppression glucose TSH risk of ARF Phenylephrine Efficacy? Morelli, et al. 28 (n = 32 pts w/septic shock) Randomized, double blind controlled trial MAP with NE vs. PE No difference in % pts achieving goal MAP, CO, SVR Safety? Morelli, et al. 28 (n = 15 pts w/septic shock) Open labeled crossover study HR with PE vs. NE splanchnic perfusion, creatinine clearance, arterial lactate Morelli A, et al. Crit Care 28;12:R143 Morelli A, et al. Shock 28;29: Survival Probability Annane 27 NE + DOB vs. EPI RR.81; p=.3 RR.75; p=.8 RR.86; p= Days Annane D, et al. Lancet 27;37: (adapted) NE + DOB EPI EPI vs. NE CAT Study NE vs. DA in Shock Study Outcomes Variable EPI NE p value Time to MAP goal, median Vasopressor free days day mortality, no (%) 31 (22.5) 36 (26.1).48 Study drug discontinued, no (%) 18 (12.9) 4 (2.8).2 6% 4% 53% p=.1 49% DA n = 1679 NE Heart rate (bpm) * p <.1 * * * EPI NE Lactate (mmol/l) 1 5 * p <.1 * * * * 2% % p<.1 24% p<.1 12% 7% 4% 28-Day Mortality Arrhythmias Skin ischemia Baseline 4h 8h 12h 16h Myburgh JA, et al. Intensive Care Med 28;34: (adapted) Baseline 4h 8h 12h 16h De Backer D, et al. N Engl J Med 21;362: American Society of Health-System Pharmacists 11
12 NE vs. DA in Septic Shock Meta Analysis Study DA n/n NE n/n 28 Day Mortality RR (95% CI) Martin 1/16 7/ ( ) Marik 6/1 5/1 1.2 ( ) Ruokonen 3/5 4/5.75 ( ) Mathur 19/25 14/ (.9 2.5) De Backer 291/ / ( ) Patel 67/134 51/ ( ) Overall 396/732 33/ ( ) Overall effect p =.35 Heterogeneity p =.77, I 2 = % De Backer D, et al. Crit Care Med 212;4: Favors DA Favors NE Vasopressin Activity Receptor Level Location Effect V1 (V1a) 1-2 pmol/l Vascular smooth muscle V2 < 1 pmol/l Renal collecting ducts V3 (V1b) Vasoconstriction Fluid retention? Anterior pituitary ACTH release Landry DW et al. N Engl J Med 21;345: Hollenberg SM. Chest 27;132: Szumita PM et al. Am J Health Sys Pharmacy 25; 62: Holmes CL et al. Crit Care 23;7: VASST Vasopressin Levels VASST NE requirements Time Norepinephrine group (pmol/l) Vasopressin group (pcmol/l) Baseline hour no change hour no change 98. Rate of NE (mcg/min) Median + IQR 25 Norepinephrine 2 15 Vasopressin Time from study drug (days) Russell JA et al. N Engl J Med. 28;358: Russell JA et al. N Engl J Med. 28;358: (adapted) VASST Mortality All Patients NE group (%) VP group (%) p value 28-day mortality day mortality Less Severe NE group (%) VP group (%) p value Shock 28-day mortality day mortality VASST Timing is Everything! Restoration of organ perfusion Antimicrobial therapy & source control Vasopressin administration Time to VP NE Mortality VP Mortality initiation < 12 hours 4.5% 33.2% > 12 hours 37.5% 37.7% Russell JA et al. N Engl J Med. 28;358: Russell JA. Crit Care 211;15: American Society of Health-System Pharmacists 12
13 Percent VASST Renal Function Using RIFLE Criteria p=.3 p=.2 p=.1 Asfar Trial MAP (mm Hg) NE rate (mcg/kg/min) Day Day 1 Day Day 1 Day Day 4 Fluid Balance (ml) RRT (%) Death 28d (%) Lowtarget ,63, ,595 2, High Target Annane ,586 2, Debacker ,1 8, Myburgh ,232 5, Rivers NA NA 3,5 1,62 NA 49 Russell ,5 11, Gordon AC, et al. Intensive Care Med 21;36:83 91 Russell JA. NEJM 214 Case (continued) MN is initiated on vasopressin at.4 units/min in addition to norepinephrine 12 mcg/min for goal MAP > 65 and UO > 4 ml/hr MAP = 62 HR = 95 CVP = 13 ScVO2 = 75 UO ~ 25 ml/hr Lactate = 4.9 With MAP and UO goals not achieved on 2 vasoactive agents, the topic of low dose corticosteroids is raised. What is your recommendation? Wait hours to see if achieve hemodynamic stability Administer hydrocortisone 2 mg/day ASAP for hemodynamic support and mortality benefit Administer the high dose ACTH stimulation test to determine cortisol response (> 9 mg/dl) Avoid corticosteroids due to immunosuppression Corticosteroids in Septic Shock 28 SCCM Recommendations IV hydrocortisone only in pts w/o BP response to fluid and vasopressor therapy No ACTH stim test No dexamethasone +/ fludrocoritsone Wean steroids if off pressors No shock = No steroids Steroids < 3 mg/d hydrocort 212 SCCM Recommendations IV hydrocortisone if no BP response to fluid and vasopressor therapy No ACTH stim test Wean steroids if off pressors No shock = No steroids Hydrocortisone 2 mg/day Hydrocortisone continuous infusions Percent PROGRESS Registry Beale R, et al. Crit Care 21;14:R American Society of Health-System Pharmacists 13
14 Diagnosis of RAI in Septic Shock Days to Shock Reversal with LD CS Steroid responsiveness (37%) Baseline cortisol 14.1 mcg/dl vs mcg/dl (p<.1) 95% pts had cortisol < 25 mcg/dl Test Steroid Responsive (Sensitivity) Steroid Unresponsive (Specificity) Random Cortisol 96% 57% Nonresponders Annane 22 CORTICUS 28 Placebo LD CS p value Placebo LD CS p value Responders <.1 All patients <.1 LD test 54% 97% HD test 22% 1% Marik PE, et al. Crit Care Med 23;31: Annane D, et al. JAMA 22;288: Sprung CL, et al. N Engl J Med 28;358: Annane 22 Mortality CORTICUS 28 Mortality p=.4 p=.96 p=.9 Percent Percent p=.69 p=1. p=.51 Annane D, et al. JAMA 22;288: Sprung CL, et al. N Engl J Med 28;358: Heterogeneity of LD CS RCTs Annane 22 SAPS II ~ 6 Placebo mortality 61% Enrolled w/in 8hr CS w/in 4hr pressor initiation MAP 55 mmhg Hydrocort + fludrocort x 7d 6% medical patients 77% non responders Appropriate antibiotics > 9% patients Time to AA ~ 6 hours CORTICUS 28 SAPS II 48 Placebo mortality 32% Enrolled w/in 72hr CS w/in?? pressor initiation SBP 94 mm Hg Hydrocort x 11d (taper) 35% medical patients 46.7% non responders Appropriate antibiotics???? Cumulative percent patients off vasopressors Early Administration of LDCS in Septic Shock Early LDCS p < Days of vasopressors Late LDCS % survival Late LDCS p =.18 Early LDCS Survival (days) Annane D, et al. JAMA 22;288: Sprung CL, et al. N Engl J Med 28;358: Katsenos CS, et al. Crit Care Med 214; 42: (adapted) 214 American Society of Health-System Pharmacists 14
15 Vasopressin and LDCS VASST Vasopressin + Low Dose Corticosteroids Percentage of Clinicians Steroids (n=589) VASST (n=779) No steroids (n=19) VP (n=296) NE (n=293) VP (n=11) NE (n=89) Patients in Septic Shock Hsu JL, et al. Crit Care 212;16: Russell JA et al. Crit Care Med 29;37: VASST VP + LDCS VP levels VASST VP + LDCS Survival Vasopressin levels (pmol/l, median + IQR) Corticosteroids No corticosteroids Baseline 6 hours 24 hours Patients who NE group (%) VP group (%) p value received steroids (n=589) 28-day mortality day mortality Days alive w/o OD (survivors) Russell JA et al. Crit Care Med 29;37: (adapted) Russell JA et al. Crit Care Med 29;37: Bauer, et al Time from pressor initiation to first CS dose = 22.2 hours Median time to withdrawal of vasopressor support (p =.9) CS = 65 hours No CS = 2 hours Patients alive w/o vasopressors at day 7 (p =.2) CS = 8.9% No CS = 47.6% CS independently associated with survival w/o vasopressors at day 7 VP + LDCS Synergy? Probability of Cumulative Survival Bauer SR, et al. J Crit Care 28;23:5 56 Torgersen C, et al. Intensive Care Med 211 (adapted) Torgersen, et al p=.1 VP + LD CS VP Days Number of days of VP infusion VP + LDCS Pilot Hydrocortisone Placebo Hydrocortisone Placebo Gordon AC, et al. Crit Care Med 214; 42: (adapted) Vasopressin received (hundred units) American Society of Health-System Pharmacists 15
16 Hydrocortisone Bolus vs. Infusion Blood glucose (mg/dl) Continuous HC (2mg/d) Bolus HC (5 mg) 3 5 mg HC 2 1 p =.47 p <.1 p =.2 Case (continued) MN is started on IV hydrocortisone 1 mg every 8 hours in addition to NE and VP infusions Blood glucose levels 198 mg/dl (pre LD CS) 235 mg/dl 31 mg/dl 228 mg/dl Hours Weber Carstens S, et al. Intensive Care Med 27;33: (adapted) Would you advocate for tight glycemic control using an intensive intravenous insulin protocol? Yes No Glycemic Control 28 SCCM Recommendations 212 SCCM Recommendations Protocolized approach Goal glucose < 15 mg/dl Monitor every 1 2 hours All patients receive glucose Caution with POCT values Protocolized approach 2 glucose levels > 18 mg/dl Upper limit 18 mg/dl Monitor every 1 2 hours Caution with POCT values Intensive Insulin Therapy Select RCTs of glucose control in the ICU Leuven I Leuven II VISEP Glucontrol NICE Sugar Population SICU MICU Sepsis Mixed Mixed Mixed ICU Centers Single Single Samp size / ~63 Excluded ,612? 34,67 Stopped early No No Yes Yes No Primary Diet TPN 85% TPN 85% 6% TPN 27% TPN 25% TPN APACHE II ~9 ~23 ~2 ~15 ~21 Mortality ICU: ~ 7% ICU: ~25% 28 D: ~27% ICU: ~16% 28 D: ~21% Hos: ~1% Hos: ~4% Hos: ~22% Protocol Leuven Leuven Leuven Variable? NICE Target Control < 18 < 18 < Hospital Mortality (%) Q1 Q2 Q3 Q4 p<.1 Glycemic Variability p<.1 p=.1 p= Mean glucose levels during ICU stay (mg/dl) Krinsley JS. Crit Care Med 28;36: (adapted) 214 American Society of Health-System Pharmacists 16
17 Mortality Probability Diabetes vs. No Diabetes Non Diabetics mg/dl mg/dl Days Post ICU Admission Lanspa MJ, et al. Chest 213;143: (adapted) Intensive Insulin Therapy What We Know Variability with POCT devices Hyperglycemia is associated with poor outcomes Hypoglycemia is associated with poor outcomes Intensive insulin therapy should be driven by protocols/guidelines to optimize efficacy and safety What We Would Like to Know Validated guidelines/protocols to ensure safety Optimal target range DM vs. Non DM Optimal glucose metrics Effect of glycemic variability Other Adjunctive Therapy Concerns in Septic Shock Management Inotropic therapy Beta blockade Immunoglobulins Mechanical ventilation PAD/NMB management Renal replacement therapy Sodium bicarbonate VTE prophylaxis Stress ulcer prophylaxis Nutrition Selenium Key Takeaways Antimicrobial therapy Must be appropriate and early Vasoactive agent(s) Resuscitation must be perfusion directed Norepinephrine preferred in majority of shock pts Low dose corticosteroids Patients with refractory shock who receive LDCS early are most likely to benefit Synergistic effect when administered with vasopressin Intensive intravenous insulin Patient specific goals depending on h/o diabetes Must be done safely Questions? Adjunctive Therapies in the Management of Septic Shock Jeremy DeGrado, PharmD BCPS Clinical Pharmacy Specialist Critical Care Brigham and Women s Hospital Boston, MA 214 American Society of Health-System Pharmacists 17
18 References Annane D, et al. Lancet 27;37: Annane D, et al. JAMA 22;288: Bangash MN, et al. Brit J Pharmacol 212;165: Bauer SR, et al. J Crit Care 28;23:5 56 Beale R, et al. Crit Care 21;14:R12 Contrael KM, et al. Crit Care Med 213:41 Dellinger RP, et al. Crit Care Med 213;41(2): Dellinger RP, et al. Crit Care Med 28;36(1): Gordon AC, et al. Intensive Care Med 21;36:83 91 Hollenberg SM, et al. Crit Care Med 24;32: Hollenberg SM. Chest 27;132: Holmes CL et al. Crit Care 23;7: Hsu JL, et al. Crit Care 212;16: Jiwaji Z, et al. Emerg Med J 213 Katsenos CS, et al. Crit Care Med 214; 42: Krinsley JS. Crit Care Med 28;36: References Landry DW et al. N Engl J Med 21;345: Lanspa MJ, et al. Chest 213;143: LeDoux D, et al. Crit Care Med 2;28: Marik PE, et al. Crit Care Med 23;31: Morelli A, et al. Crit Care 28;12:R143 Morelli A, et al. Shock 28;29: Myburgh JA, et al. Intensive Care Med 28;34: Russell JA et al. N Engl J Med. 28;358: Russell JA et al. Crit Care Med 29;37: Russell JA. Crit Care 211;15: Sprung CL, et al. N Engl J Med 28;358: Szumita PM et al. Am J Health Sys Pharmacy 25; 62: Szumita PM et al. Am J Health Syst Pharm 26;63; Torgersen C, et al. Intensive Care Med 211 Weber Carstens S, et al. Intensive Care Med 27;33: American Society of Health-System Pharmacists 18
Evidence-Based. Management of Severe Sepsis. What is the BP Target?
Evidence-Based Management of Severe Sepsis Michael A. Gropper, MD, PhD Professor and Vice Chair of Anesthesia Director, Critical Care Medicine Chair, Quality Improvment University of California San Francisco
More informationObjectives. Management of Septic Shock. Definitions Progression of sepsis. Epidemiology of severe sepsis. Major goals of therapy
Objectives Management of Septic Shock Review of the Evidence and Implementation of Pediatric Guidelines at Christus Santa Rosa Manish Desai, M.D. PL 5 2 nd year Pediatric Critical Care Fellow Review of
More informationNothing to disclose 9/25/2017
Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Nothing to disclose 1 Explain
More information9/25/2017. Nothing to disclose
Nothing to disclose Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Explain
More informationSepsis: Identification and Management in an Acute Care Setting
Sepsis: Identification and Management in an Acute Care Setting Dr. Barbara M. Mills DNP Director Rapid Response Team/ Code Resuscitation Stony Brook University Medical Center SEPSIS LECTURE NPA 2018 OBJECTIVES
More informationControversies in Hospital Medicine: Critical Care. Vasopressors, Steroids, and Insulin Therapy
Controversies in Hospital Medicine: Critical Care Vasopressors, Steroids, and Insulin Therapy Douglas Fish, Pharm.D. Professor of Pharmacy, University of Colorado Denver Clinical Specialist in Critical
More informationObjectives. Epidemiology of Sepsis. Review Guidelines for Resuscitation. Tx: EGDT, timing/choice of abx, activated
Update on Surviving Sepsis 2008 Objectives Epidemiology of Sepsis Definition of Sepsis and Septic Shock Review Guidelines for Resuscitation Dx: Lactate, t cultures, SVO2 Tx: EGDT, timing/choice of abx,
More informationSepsis Management Update 2014
Sepsis Management Update 2014 Laura J. Moore, MD, FACS Associate Professor, Department of Surgery The University of Texas Health Science Center, Houston Medical Director, Shock Trauma ICU Texas Trauma
More informationEarly Goal-Directed Therapy
Early Goal-Directed Therapy Where do we stand? Jean-Daniel Chiche, MD PhD MICU & Dept of Host-Pathogen Interaction Hôpital Cochin & Institut Cochin, Paris-F Resuscitation targets in septic shock 1 The
More informationSepsis Management: Past, Present, and Future
Sepsis Management: Past, Present, and Future Benjamin Ferrell, MD Tennessee ACP Meeting October 28, 2017 Learning Objectives Identify the most updated definition and clinical criteria for sepsis Describe
More informationEFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK. Alexandria Rydz
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK Alexandria Rydz BACKGROUND- SEPSIS Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated
More informationJohn Park, MD Assistant Professor of Medicine
John Park, MD Assistant Professor of Medicine Faculty photo will be placed here park.john@mayo.edu 2015 MFMER 3543652-1 Sepsis Out with the Old, In with the New Mayo School of Continuous Professional Development
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationSurviving Sepsis Campaign Guidelines 2012 & Update for David E. Tannehill, DO Critical Care Medicine Mercy Hospital St.
Surviving Sepsis Campaign Guidelines 2012 & Update for 2015 David E. Tannehill, DO Critical Care Medicine Mercy Hospital St. Louis Be appropriately aggressive the longer one delays aggressive metabolic
More informationCORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE
CORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE 1 ABBREVIATIONS ACCP = American College of Chest Physicians ARF =
More informationDiagnosis and Management of Sepsis and Septic Shock. Martin D. Black MD Concord Pulmonary Medicine Concord, New Hampshire
Diagnosis and Management of Sepsis and Septic Shock Martin D. Black MD Concord Pulmonary Medicine Concord, New Hampshire Financial: none Disclosures Objectives: Identify physiologic principles of septic
More informationVasopressors in Septic Shock. Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada
Vasopressors in Septic Shock Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada Echocardiogram: EF=25% 57 y.o. female, pneumonia, shock Echocardiogram: EF=25% 57 y.o.
More informationThe syndrome formerly known as. Severe Sepsis. James Rooks MD. Coordinator of critical care education OU College of Medicine, Tulsa
The syndrome formerly known as Severe Sepsis James Rooks MD Coordinator of critical care education OU College of Medicine, Tulsa Disclosures I have no actual or practical conflicts of interest in relation
More informationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care
More information4/5/2018. Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY. I have no financial disclosures
Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY I have no financial disclosures 1 Objectives Why do we care about sepsis Understanding the core measures by Centers for Medicare
More informationThe Ever Changing World of Sepsis Management. Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital
The Ever Changing World of Sepsis Management Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital COI Disclosures No financial interests to disclose Learning Objectives Review the evolution
More informationUpdates in Sepsis 2017
Mortality Cases Total U.S. Population/1,000 Updates in 2017 Joshua Solomon, M.D. Associate Professor of Medicine National Jewish Health University of Colorado Denver Background New Definition of New Trials
More informationSEPSIS 2015 DISCLOSURES FINANCIAL DISCLOSURES 9/1/2015. William M. Johnson, MD Nebraska Pulmonary Specialties. William Johnson
SEPSIS 2015 William M. Johnson, MD Nebraska Pulmonary Specialties 1 DISCLOSURES William Johnson No financial interests related to this presentation 2 FINANCIAL DISCLOSURES I do however have 3 children
More informationFluid Resuscitation and Monitoring in Sepsis. Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS
Fluid Resuscitation and Monitoring in Sepsis Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS Learning Objectives Compare and contrast fluid resuscitation strategies in septic shock Discuss available
More informationSeptic Shock. Rontgene M. Solante, MD, FPCP,FPSMID
Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage
More informationSepsis overview. Dr. Tsang Hin Hung MBBS FHKCP FRCP
Sepsis overview Dr. Tsang Hin Hung MBBS FHKCP FRCP Epidemiology Sepsis, severe sepsis, septic shock Pathophysiology of sepsis Recent researches and advances From bench to bedside Sepsis bundle Severe sepsis
More informationPatient Safety Safe Table Webcast: Sepsis (Part III and IV) December 17, 2014
Patient Safety Safe Table Webcast: Sepsis (Part III and IV) December 17, 2014 Presenters Mark Blaney, RN Regional Nurse Educator CHI Franciscan Health Karen Lautermilch Director, Quality & Performance
More informationFluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE
Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE In critically ill patients: too little fluid Low preload,
More informationSurviving Sepsis. Brian Woodcock MBChB MRCP FRCA FCCM
1 Surviving Sepsis Brian Woodcock MBChB MRCP FRCA FCCM 2 Disclosures No conflicts of interest 3 Sepsis Principles of management of septic shock in the operating room "Surviving Sepsis" guidelines 4 Add-on
More informationWhat works in sepsis. Topics. EGDT: Severe Sepsis/ Shock. Sepsis
What works in sepsis Eric Schmidt, MD Denver Health Medical Center University of Colorado School of Medicine Topics Understanding and implemen@ng early goal directed therapy (EGDT) Ac@vated Protein C should
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationThe Septic Patient. Dr Arunraj Navaratnarajah. Renal SpR Imperial College NHS Healthcare Trust
The Septic Patient Dr Arunraj Navaratnarajah Renal SpR Imperial College NHS Healthcare Trust Objectives of this session Define SIRS / sepsis / severe sepsis / septic shock Early recognition of Sepsis The
More information6/5/2014. Sepsis Management and Hemodynamics. 2004: International group of experts,
Sepsis Management and Hemodynamics Javier Perez-Fernandez, M.D., F.C.C.P. Medical Director Critical Care Services, Baptist t Hospital of Miamii Medical Director Pulmonary Services, West Kendall Baptist
More informationSepsis and Hemodynamic Support in September 15, 2017 Carleen Risaliti
Sepsis and Hemodynamic Support in 2017 September 15, 2017 Carleen Risaliti Objectives Review fluid resuscitation guidelines in septic shock Discuss volume assessment v. fluid responsiveness Evaluate pros
More informationtowards early goal directed therapy
Paediatric Septic Shock- towards early goal directed therapy Elliot Long Paediatric Acute Care 2011 Conference Outline Emergency Department Rivers Protocol (EGDT) ACCM Sepsis Protocol Evidence Barriers
More informationSepsis: Update on Diagnosis, Evaluation and Management
Sepsis: Epidemiology Sepsis: Update on Diagnosis, Evaluation and Management Michael J. Apostolakos, MD Professor of Medicine Director of Adult Critical Care University of Rochester ~ 750,000 cases per
More informationUpdate in Critical Care Medicine
Update in Critical Care Medicine Michael A. Gropper, MD, PhD Professor and Executive Vice Chair Department of Anesthesia and Perioperative Care Director, Critical Care Medicine UCSF Disclosure None Update
More informationActualités de la prise en charge hémodynamique initiale Daniel De Backer
Actualités de la prise en charge hémodynamique initiale Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles Past- President European
More informationManagement of Severe Sepsis:
Management of Severe Sepsis: Update from the Surviving Sepsis Campaign Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University NONE Disclosures Review evidence-based international sepsis
More informationStaging Sepsis for the Emergency Department: Physician
Staging Sepsis for the Emergency Department: Physician Sepsis Continuum 1 Sepsis Continuum SIRS = 2 or more clinical criteria, resulting in Systemic Inflammatory Response Syndrome Sepsis = SIRS + proven/suspected
More informationOHSU. Update in Sepsis
Update in Sepsis Jonathan Pak, MD June 1, 2017 Structure of Talk 1. Sepsis-3: The latest definition 2. Clinical Management - Is EGDT dead? - Surviving Sepsis Campaign Guidelines 3. A novel therapy: Vitamin
More informationThe Use of Metabolic Resuscitation in Sepsis
The Use of Metabolic Resuscitation in Sepsis Jennifer M. Roth, PharmD, BCPS, BCCCP Critical Care Clinical Specialist - Surgical Trauma ICU Baylor University Medical Center Disclosures No conflicts of interest
More informationNo conflicts of interest to disclose
No conflicts of interest to disclose Introduction Epidemiology Surviving sepsis guidelines 2012 Updates Resuscitation protocols Map Goals Transfusion Sepsis-3 Bundle Management Questions Sepsis is a systemic,
More informationSepsis Update: Focus on Early Recognition and Intervention. Disclosures
Sepsis Update: Focus on Early Recognition and Intervention Jessie Roske, MD October 2017 Disclosures I have no actual or potential conflict of interest in relation to this program/presentation. I will
More informationINTENSIVE CARE MEDICINE CPD EVENING. Dr Alastair Morgan Wednesday 13 th September 2017
INTENSIVE CARE MEDICINE CPD EVENING Dr Alastair Morgan Wednesday 13 th September 2017 WHAT IS NEW IN ICU? (RELEVANT TO ANAESTHETISTS) Not much! SURVIVING SEPSIS How many deaths in England were thought
More informationEarly Goal Directed Therapy in 2015: What Did the Big Trials Teach us?
Early Goal Directed Therapy in 2015: What Did the Big Trials Teach us? Mitchell M. Levy MD, FCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care Warren Alpert Medical School
More informationInflammation. Sepsis Ladder
Maureen Maloney-Poldek MSN, RN Chamberlain College of Nursing Pathophysiology of sepsis and septic shock How sepsis affects the endocrine system Pathophysiology of adrenal insufficiency Clinical manifestations
More informationSHOCK. Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital
SHOCK Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital 1 Definition Shock is an acute, complex state of circulatory dysfunction
More informationVasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis
Vasoactive Medications Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis Objectives List components of physiology involved in blood pressure Review terminology related
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationShould we use steroids in sepsis? J.G. van der Hoeven
Should we use steroids in sepsis? J.G. van der Hoeven Why I don t like it It is boring.. It usually results in emotional outcries in the audience If any, the effects on outcome are very small You are not
More informationRalph Palumbo, MD, FCCP
Ralph Palumbo, MD, FCCP Septic shock is the leading cause of mortality in patients admitted to the ICU In the United States alone there are over 750,000 cases of severe sepsis and septic shock annually
More informationAnnMarie Papa, DNP,RN,CEN,NE-BC,FAEN, FAAN Clinical Director, Emergency, Medical & Observation Nursing Hospital of the University of Pennsylvania
AnnMarie Papa, DNP,RN,CEN,NE-BC,FAEN, FAAN Clinical Director, Emergency, Medical & Observation Nursing Hospital of the University of Pennsylvania Who Am I? Except on few occasions, the patient appears
More informationLooking for sepsis. Sepsis: Update. Prevalence of High Profile Dzs. Screening and risk stratification. Mortality of High Profile Diseases
Sepsis: Update Prevalence of High Profile Dzs Edward A. Panacek, MD, MPH Professor and Chair, Emergency Medicine USA Medical Center, Mobile, AL NDAFP Conference Big Sky. 2016 Syllabus Angus Crit Care Med
More informationSurviving Sepsis Campaign
Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis/Septic Shock An Overview By professor Ahmad Alaysh BMC-MICU 1 Surviving Sepsis A global program to Reduce mortality rates in severe
More informationCase year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50
Case 1 65 year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50 Case 1 65 year old female nursing home resident with
More informationManaging Patients with Sepsis
Managing Patients with Sepsis Diagnosis; Initial Resuscitation; ARRT Initiation Prof. Achim Jörres, M.D. Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
More informationSepsis New Management Strategies
Sepsis: Epidemiology Sepsis 2013- New Management Strategies Michael J. Apostolakos, MD Professor of Medicine Director of Adult Critical Care University of Rochester ~ 750,000 cases per year ~200,000 deaths
More informationVasopressors for shock
Vasopressors for shock Background Reviews and Observational Studies Holler 2015. Nontraumatic Hypotension and Shock in the Emergency Department and Prehospital Setting Prevalence, Etiology and Mortality:
More informationUPDATES IN SEPSIS MANAGEMENT Shannon Fry, Pharm.D. Critical Care Pharmacy Specialist St. Joseph Medical Center
UPDATES IN SEPSIS MANAGEMENT Shannon Fry, Pharm.D. Critical Care Pharmacy Specialist St. Joseph Medical Center ShannonFry@fhshealth.org DISCLOSURE I have no financial relationships to disclose OBJECTIVES
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationBC Sepsis Network Emergency Department Sepsis Guidelines
The provincial Sepsis Clinical Expert Group developed the BC, taking into account the most up-to-date literature (references below) and expert opinion. For more information about the guidelines, and to
More informationVOLUME RESPONSIVENESS IS DIFFERENT FROM NEED FOR FLUIDS BLOOD PRESSURE TARGETS IN SEPSIS
Department of Intensive Care Medicine VOLUME RESPONSIVENESS IS DIFFERENT FROM NEED FOR FLUIDS BLOOD PRESSURE TARGETS IN SEPSIS SEPTIC SHOCK : THE CLINICAL SCENARIO HYPOTENSION DESPITE ADEQUATE VOLUME RESUSCITATION
More informationFLUID RESUSCITATION AND MONITORING IN SEPSIS PROTOCOLIZED VS USUAL CARE DEEPA BANGALORE GOTUR MD, FCCP ASSISTANT PROFESSOR, WEILL CORNELL MEDICAL
FLUID RESUSCITATION AND MONITORING IN SEPSIS PROTOCOLIZED VS USUAL CARE DEEPA BANGALORE GOTUR MD, FCCP ASSISTANT PROFESSOR, WEILL CORNELL MEDICAL COLLEGE NOVEMBER 10 TH 2017 TEXAS SCCM SYMPOSIUM Disclosures
More informationEndocrine and Metabolic Complications in the ICU
Endocrine and Metabolic Complications in the ICU Linda Liu, M.D. Associate Professor UCSF Department of Anesthesia UC SF 1 New Progress Discovery of complex neuro-endocrine adaptation to critical illness
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More information4/4/2014. Of patients diagnosed with sepsis 50% will develop severe sepsis 25% will develop shock. SIRS Sepsis Severe Septic Sepsis Shock.
A summary of pathophysiology, therapeutics, and how the pharmacy TECHNICIAN can help improve OUTCOMES Anthony Nelson 2014 Pharm.D. Candidate Tricia Aggers, Pharm.D. Affiliate Faculty, ISU College of Pharmacy
More informationEarly-goal-directed therapy and protocolised treatment in septic shock
CAT reviews Early-goal-directed therapy and protocolised treatment in septic shock Journal of the Intensive Care Society 2015, Vol. 16(2) 164 168! The Intensive Care Society 2014 Reprints and permissions:
More informationSepsis Learning Collaborative: Sepsis New Definitions
Sepsis Learning Collaborative: Sepsis New Definitions Sepsis 3, a New Definition Todd L. Slesinger, MD, FACEP, FCCM, FCCP, FAAEM Program Director and Academic Chair Department of Emergency Medicine Disclosures
More informationSurviving Sepsis: A CRASH Course. Justin Jones, PharmD Sanford Medical Center, Fargo Staff Education 2015
Surviving Sepsis: A CRASH Course Justin Jones, PharmD Sanford Medical Center, Fargo Staff Education 2015 Disclosures No financial conflicts of interest Abbreviations ULN Upper limit of normal SVCO2 Central
More informationTitrating Critical Care Medications
Titrating Critical Care Medications Chad Johnson, MSN (NED), RN, CNCC(C), CNS-cc Clinical Nurse Specialist: Critical Care and Neurosurgical Services E-mail: johnsoc@tbh.net Copyright 2017 1 Learning Objectives
More informationThe Pharmacology of Hypotension: Vasopressor Choices for HIE patients. Keliana O Mara, PharmD August 4, 2018
The Pharmacology of Hypotension: Vasopressor Choices for HIE patients Keliana O Mara, PharmD August 4, 2018 Objectives Review the pathophysiology of hypotension in neonates Discuss the role of vasopressors
More informationAdvancements in Sepsis
Objectives Advancements in Sepsis Brian Gilbert, PharmD PGY-1 Pharmacy Resident Jackson Memorial Hospital 3/13/2016 www.fshp.org Pharmacist objectives Review recent updates in resuscitation strategies
More informationSepsis. From EMS to ER to ICU. What we need to be doing
Sepsis From EMS to ER to ICU What we need to be doing NEHAL BHATT, MD ATHENS PULMONARY, CRITICAL CARE AND SLEEP Objectives 1. Define the changes to the definition of Sepsis 2. Describe the assessment,
More informationBillion
Surviving : Are we? The 7th National Emergency Medicine Congress Antalya, Turkey Alexander L. Eastman, MD, MPH Department of Surgery UTSW Severe : A Significant Healthcare Challenge Major cause of morbidity
More informationThe Management of Septic Shock
The Management of Septic Shock Anthony J. Courey, MD Assistant Professor of Medicine Associate Director, CCMU Pulmonary & Critical Care Medicine No conflicts No disclosures Conflicts & Disclosures Overview
More informationThe changing face of
The changing face of sepsis. @SepsisUK Dr Ron Daniels B.E.M. CEO, UK Sepsis Trust CEO, Global Sepsis Alliance Special Adviser (maternal sepsis) to WHO Breast cancer Cognitive impairment Mild 3.8 7.1
More informationSepsis: Management ANUPOL PANITCHOTE, MD. Division of Critical Care Medicine Department of Medicine, Khon Kaen University, Thailand
Sepsis: Management ANUPOL PANITCHOTE, MD. Division of Critical Care Medicine Department of Medicine, Khon Kaen University, Thailand Vital signs Symptoms LAB BT > 38.3 or < 36 ๐ C HR > 90 bpm RR > 20 /min
More informationEARLY GOAL DIRECTED THERAPY : seminaires iris. Etat des lieux en Daniel De Backer
EARLY GOAL DIRECTED THERAPY : Etat des lieux en 2017 Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles Past-President European
More informationSepsis and septic shock: can we win the battle against this hidden crisis?
REVIEW ARTICLE Sepsis and septic shock: can we win the battle against this hidden crisis? V.G. Dassanayake Department of Surgery, Faculty of Medicine, University of Colombo, Sri Lanka Key words : Sepsis;
More informationTiming of Vasopressors in Septic Shock: How Soon is Too Soon?
Timing of Vasopressors in Septic Shock: How Soon is Too Soon? Anand Kumar, MD Sections of Critical Care Medicine and Infectious Diseases Professor of Medicine, Medical Microbiology and Pharmacology University
More informationR2R: Severe sepsis/septic shock. Surat Tongyoo Critical care medicine Siriraj Hospital
R2R: Severe sepsis/septic shock Surat Tongyoo Critical care medicine Siriraj Hospital Diagnostic criteria ACCP/SCCM consensus conference 1991 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
More informationShould Roids Be the Rage in Septic Shock? Lauren Powell, MSN, RN, CCRN, AGACNP-BC CHI Baylor St. Luke s Medical Center, Houston, TX
Should Roids Be the Rage in Septic Shock? Lauren Powell, MSN, RN, CCRN, AGACNP-BC CHI Baylor St. Luke s Medical Center, Houston, TX Learning Objectives 1. Review the mechanism of action for the use of
More informationSepsis Story At Intermountain Healthcare Intensive Medicine Clinical Program
Sepsis Story At Intermountain Healthcare 2004-2012 Intensive Medicine Clinical Program The International Surviving Sepsis Campaign Was Organized In 2002 During The ESICM International Meeting In Barcelona,
More informationUpdate in Sepsis. Conflicts of Interest: None. Bill Janssen, M.D.
Update in Sepsis Bill Janssen, M.D. Associate Professor of Medicine National Jewish Health University of Colorado Denver Conflicts of Interest: None A 62 year-old female presents to the ED with fever,
More informationEpidemiology of Severe Sepsis
Dellinger et al Crit Care Med 2008 Surviving Sepsis Phase I: the Barcelona Declaration Phase II: development and publication of guidelines 2004, updated in 2008 Phase III: operationalize the guidelines,
More informationWhere did it all begin?
EXPLORE Healthcare Summit Sepsis: Can We Finally Just Relax on the SOFA? Mark Keuchel, D.O. Background: 1. Sepsis is a wide-spectrum disease process that remains poorly understood 2. Early-goal directed
More informationDr. F Javier Belda Dept. Anesthesiology and Critical Care Hospital Clinico Universitario Valencia (Spain) Pulsion MAB
State of the Art Hemodynamic Monitoring III CO, preload, lung water and ScvO2 The winning combination! Dr. F Javier Belda Dept. Anesthesiology and Critical Care Hospital Clinico Universitario Valencia
More informationFluid balance and clinically relevant outcomes
Fluid balance and clinically relevant outcomes Rui Moreno, MD, PhD, Professor UCINC, Hospital de São José Centro Hospitalar de Lisboa Central, E.P.E. INSULT PRIMARY MODS SIRS SECONDARY MODS OUTCOME RECOVERY
More information2016 Sepsis Update: Pearls, Pitfalls, and Core Measure Quicksand
2016 Sepsis Update: Pearls, Pitfalls, and Core Measure Quicksand Jack Perkins, MD FACEP, FAAEM, FACP Assistant Professor of Emergency and Internal Medicine Virginia Tech Carilion School of Medicine Why
More informationCardiovascular Management of Septic Shock
Cardiovascular Management of Septic Shock R. Phillip Dellinger, MD Professor of Medicine Robert Wood Johnson Medical School/UMDNJ Director, Critical Care Medicine and Med/Surg ICU Cooper University Hospital
More informationTHE CRITICALLY ILL OLDER PERSON WITH: SEPTIC SHOCK
THE CRITICALLY ILL OLDER PERSON WITH: SEPTIC SHOCK Older people carry the burden of sepsis Older people carry the burden of sepsis Immunosenescence Co-morbidity Endothelial / mucosal atrophy Dependence
More informationTop Sepsis Studies
A75M233/A75M529 Monday 08:00-09:15 Wednesday 14:45-16:00 Maureen A Seckel APRN, ACNS-BC, CCRN, CCNS, FCCM Critical Care CNS and Sepsis Leader Christiana Care Health Services, Newark, DE Top Sepsis Studies
More informationPresented by: Indah Dwi Pratiwi
Presented by: Indah Dwi Pratiwi Normal Fluid Requirements Resuscitation Fluids Goals of Resuscitation Maintain normal body temperature In most cases, elevate the feet and legs above the level of the heart
More informationAcute Liver Failure: Supporting Other Organs
Acute Liver Failure: Supporting Other Organs Michael A. Gropper, MD, PhD Professor of Anesthesia and Physiology Director, Critical Care Medicine University of California San Francisco Acute Liver Failure
More informationCritical Care Medicine Update for Non-Intensivists 2015
27 March 2015 Boca Raton Critical Care Medicine Update for Non-Intensivists 2015 MARGARET M. JOHNSON, MD CHAIR, DIVISION OF PULMONARY MEDICINE MAYO CLINIC FLORIDA Critical Care Medicine Update for The
More informationPediatric Sepsis Treatment:
Disclosures Pediatric Sepsis Treatment: (treat) Early & (reevaluate) Often None June 11, 2018 Leslie Dervan, MD MS Pacific Northwest Sepsis Conference 1 Agenda Sepsis: pathophysiology at-a-glance Pediatric
More information9/13/2015. Laboratory. HPI and PE
Critical Care HPI and PE 74 yo male confused SBP 90/20 MAP50, P 122, RR 34 Ox1 w/o nuchal rigidity S1S2 wo m RLL reduced breath sounds Skin warm dry Laboratory» WBC 15,600 Hgb 8.4 HCt 23%, Plts 95000,
More informationการอบรมว ทยาศาสตร พ นฐานทางศ ลยศาสตร เร อง นพ.ส ณฐ ต โมราก ล ภาคว ชาว ส ญญ ว ทยา คณะแพทยศาสตร โรงพยาบาลรามาธ บด มหาวทยาลยมหดล
การอบรมว ทยาศาสตร พ นฐานทางศ ลยศาสตร เร อง นพ.ส ณฐ ต โมราก ล ภาคว ชาว ส ญญ ว ทยา คณะแพทยศาสตร โรงพยาบาลรามาธ บด มหาวทยาลยมหดล Distributive shock Severe sepsis and Septic shock Anaphylactic shock Neurogenic
More informationSepsis Care and the New Core Measures. Daniel S. Hagg, MD January 15, 2016
Sepsis Care and the New Core Measures Daniel S. Hagg, MD January 15, 2016 Outline What is sepsis? A brief history of sepsis care How should we take care of septic patients now? Core measures What strategies
More information